{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"60"}],"units":"Participants"}],"groups":[{"description":"Azacitidine (AZA) 75 mg/m\\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib starting dose 200 mg orally twice a day for 28 Day cycle.","id":"BG000","title":"Phase I: Azacitidine + Sorafenib"},{"description":"Azacitidine (AZA) 75 mg/m\\^2 subcutaneously (SQ) or intravenously (IV) daily for 7 days and Sorafenib 400 mg orally twice a day for 28 Day cycle.","id":"BG001","title":"Phase II: Azacitidine + 400 Sorafenib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"40","upperLimit":"87","value":"73"},{"groupId":"BG001","lowerLimit":"20","upperLimit":"81","value":"64"},{"groupId":"BG002","lowerLimit":"20","upperLimit":"87","value":"64"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"28"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"32"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"60"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}